Athanor Capital, LP Argenx Se Transaction History

Athanor Capital, LP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$257.11 - $319.92 $358,925 - $446,608	-1,396 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$268.3 - $380.31 $781,557 - $1.11 Million	-2,913 Reduced 67.6%	1,396 $384,000
Q4 2020 Feb 16, 2021	BUY	$248.13 - $308.36 $197,263 - $245,146	795 Added 22.62%	4,309 $1.27 Million
Q3 2020 Nov 16, 2020	BUY	$215.51 - $272.51 $343,738 - $434,653	1,595 Added 83.12%	3,514 $922,000
Q2 2020 Aug 13, 2020	BUY	$127.44 - $232.72 $244,557 - $446,589	1,919 New	1,919 $432,000
Q1 2020 May 14, 2020	SELL	$108.83 - $165.23 $306,138 - $464,791	-2,813 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$106.59 - $164.21 $299,837 - $461,922	2,813 New	2,813 $452,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Athanor Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Athanor Capital, LP with notifications on news.